

## Supplementary Appendix

**Supplemental Figure S1.** Flowchart visualizing enrollment, dose-group assignment, and follow-up. In this example, the patient would be included in the high dose group because the LAmB dose at the time of AKI was  $> 7$  mg/kg/day. They would then be followed until complete recovery, death, discharge, or for 30 days after LAmB-associated nephrotoxicity, whichever occurred first. Outcomes were subdivided according to study definitions into no recovery, partial recovery, and complete recovery.

**Figure S1 – Sample patient enrollment schematic**

